Prozkoumejte nejčtenější články a videa na Campus Sanofi
Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more
The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more
Niemann-Pick: Comprendre le déficit en sphingomyélinase acide en 4 minutes
The Bright study demonstrated similar efficacy and safety of Toujeo® (Glargine 300 U/ml) compared to degludec 100 U/ml in type 2 diabetes patients who had not previously received basal insulin1.
The Bright study demonstrated similar efficacy and safety of Toujeo® (Glargine 300) compared to degludec (insulin degludec) in type 2 diabetes patients who had not previously received basal insulin1.
May 17–21, 2025; San Francisco, California, US